A dual-specific CRISPR-Cas nanosystem for precision therapeutic editing of liver disorders

Signal Transduct Target Ther. 2022 Aug 12;7(1):269. doi: 10.1038/s41392-022-01071-2.

Authors

Xiaojie Xu^#¹, Honglin Tang^#^{1

2}, Jiajing Guo¹, Huhu Xin¹, Yuan Ping^{3

4}

Affiliations

¹ College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
² Department of Medical Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310058, China.
³ College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China. pingy@zju.edu.cn.
⁴ Liangzhu Laboratory, Zhejiang University Medical Center, 1369 West Wenyi Road, Hangzhou, 311121, China. pingy@zju.edu.cn.

^# Contributed equally.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

CRISPR-Cas Systems* / genetics
Gene Editing
Humans
Liver Diseases* / genetics
Liver Diseases* / therapy